CSIMarket


Atea Pharmaceuticals Inc   (AVIR)
Other Ticker:  
 


 

Atea Pharmaceuticals Inc

AVIR's Financial Statements and Analysis



Atea Pharmaceuticals Inc increased third quarter of 2023 net loss per share of $-0.40 compare to net loss per share of $-0.10 recorded in the same quarter a year ago a decrease compare to $-0.34 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.4 $  0 Mill
$-0.30     Unch.    



Atea Pharmaceuticals Inc 's Revenue fell by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


Atea Pharmaceuticals Inc is

More on AVIR's Income Statement



Atea Pharmaceuticals Inc 's in thethird quarter of 2023 recorded net loss of $-33.142 million, an increase from net loss of $-8.066 million in III. Quarter a year ago.

Sequentially net loss advanced

More on AVIR's Growth

Atea Pharmaceuticals Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-76 million


Atea Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Atea Pharmaceuticals Inc payed $ -1.02 cash per share, on a free-cash flow basis .

Book value fell by -3.42 % sequentially to $6.98 per share, -15.64% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 6.98 per share from $ 7.22.

Company issued 0.00 million shares or 0.00 % in Sep 30 2023.


More on AVIR's Dividends

 Market Capitalization (Millions) 334
 Shares Outstanding (Millions) 83
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -131
 Cash Flow (TTM) (Millions $) -39
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 12




Atea Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Atea Pharmaceuticals Inc had negative $ -1.02 cash flow per share, on a free-cash flow basis .

Book value fell by -3.42 % sequentially to $6.98 per share, -15.64% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 6.98 per share from $ 7.22.

Company issued 0.00 million shares or 0.00 % in Sep 30 2023.


More on AVIR's Balance Sheets

 Market Capitalization (Millions) 334
 Shares Outstanding (Millions) 83
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -131
 Cash Flow (TTM) (Millions $) -39
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 12
   


  News about Atea Pharmaceuticals Inc Earnings

Atea Pharmaceuticals Inc. Releases Impressive Q3 2023 Results, Announced by AVIR

Investors in the Major Pharmaceutical Preparations sector are closely watching the performance of Atea Pharmaceuticals Inc as they interpret its third-quarter 2023 results. The company recently announced an operating shortfall of $-40.785 million for the period from July to September 30, 2023. Notably, Atea Pharmaceuticals Inc has not yet disclosed any revenue figures.
To gain further context, experts are comparing the current performance with that of the third quarter of 2022. During that period, the company reported an operating shortfall of $-16.281 million. It comes as no surprise that the evolving organization experienced a net loss of $-33.142 million, an increase from the $-8.066 million loss repo...

AVIR's Major Pharmaceutical Preparations Market Shows Significant Growth in Q2 2023

Atea Pharmaceuticals Inc is a company that has recently caught the attention of investors due to its financial performance and potential in the pharmaceutical industry. While the company's revenue has not been predicted to undergo any significant modifications during the earnings cycle between April and June 2023, investors have observed a notable operating loss during this period.
During the mentioned time frame, Atea Pharmaceuticals Inc recorded an operating loss of $-35.235 million. Although this may raise concerns among investors, it is important to analyze the situation in the context of the company's overall performance. By comparing the operating loss of the second quarter of 2022, which amounted ...


Date modified: 2023-11-10T00:20:51+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com